Effects of colforsin, trequinsin and isoprenaline on norepinephrine-induced contractions and cyclic nucleotide levels of isolated vascular tissue.
Recent observations imply the involvement of an endothelium-derived relaxing factor (EDRF) in the vasodilation of isolated vascular preparations accompanied by an increase of cyclic guanosine 3',5'-monophosphate (cGMP). To investigate the changes of cGMP and cyclic adenosine 3',5'-monophosphate (cAMP) in endothelium-dependent relaxation of isolated rabbit thoracic aortic rings we used colforsin (forskolin, FOR) as an adenylate cyclase stimulator, trequinsin (TRE) as a phosphodiesterase inhibitor and isoprenaline (ISO) as a beta-adrenoceptor agonist. Norepinephrine (NE, 10(-8) mol/l) evoked a contractile response in intact rings of rabbit aorta. In these precontracted rings with endothelium, acetylcholine (ACh) induced a concentration-dependent relaxation at 10(-8)-10(-6) mol/l. FOR, TRE and ISO reduced NE-vasoconstrictor responses in a concentration-dependent manner with an IC50 of 4.1 x 10(-8) mol/l, 8.5 x 10(-7) mol/l and 4.0 x 10(-7) mol/l, respectively, in rabbit aortic rings with endothelium. These effects were associated with elevations (p less than 0.05) in cAMP and cGMP in vascular tissue. In segments with disrupted endothelium the IC50 for FOR and TRE were increased about 3.5- and 2.3-fold, without changes in cyclic nucleotides. All three compounds attenuated ACh-induced relaxations of aortic rings in a concentration-dependent manner. High concentrations of FOR (10(-7) mol/l) and TRE (10(-5)) which increased cAMP even reversed ACh-induced relaxations, comparable to ACh effects in de-endothelialized vascular tissue. It is suggested that FOR-, TRE- and ISO-induced relaxations of isolated aortic preparations, accompanied by increased cAMP, interact with EDRF-dependent relaxations.
Linz
W
W
Hoechst Aktiengesellschaft Frankfurt/Main, Fed. Rep. of Germany.
Wiemer
G
G
Schölkens
B A
BA
D000109:Acetylcholine / Q000378:metabolism; D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects / Q000378:metabolism; D005576:Colforsin / Q000494:pharmacology*; D000242:Cyclic AMP / Q000378:metabolism; D006152:Cyclic GMP / Q000378:metabolism; D005260:Female; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology*; D007546:Isoquinolines / Q000494:pharmacology*; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects* / Q000378:metabolism; D009638:Norepinephrine / Q000494:pharmacology*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011817:Rabbits; D044005:Tetrahydroisoquinolines
D007546:Isoquinolines; D010975:Platelet Aggregation Inhibitors; D044005:Tetrahydroisoquinolines; D005576:Colforsin; C035964:trequinsin; D000242:Cyclic AMP; D006152:Cyclic GMP; D007545:Isoproterenol; D000109:Acetylcholine; D009638:Norepinephrine